Glivec leukaemia drug action

Référence de la vidéo 11930021
Glivec leukaemia drug binding to its target, the enzyme Bcr-Abl tyrosine kinase. This enzyme is produced by a genetic mutation, the swapping of parts of two chromosomes, leading to the formation of the oncogene (cancer-causing gene) Bcr-Abl, which produces a constantly-active version of normal Abl tyrosine kinase. This causes chronic myelogenous leukaemia (CML), a cancer of white blood cells. The drug Glivec (Imatinib) works by binding to the active site of the Bcr-Abl enzyme, producing a change in shape that prevents the enzyme from functioning. This causes the death of cancerous cells expressing the enzyme. Glivec, the first such tyrosine kinase inhibitor to be produced, is marketed by Novartis.
Licence : Droits gérés
Crédit : Science Photo Library / Andrade, Ramon / 3dciencia
Model Release : Non requis
Property release : Non requis
Durée : 10 Secondes
Aspect ratio : 16/9
Restrictions : -

Prix pour cette vidéo À partir de 70 €

Publicité (Communication d'entreprise etc) À partir de 70 €
Rédactionnel (Sites web multiples etc) À partir de 125 €
Médias (Émission TV, Divertissement TV etc) À partir de 150 €

Mots-clés

;